Copperwynd Financial LLC Purchases 35 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Copperwynd Financial LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.6% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 788 shares of the biopharmaceutical company’s stock after purchasing an additional 35 shares during the quarter. Copperwynd Financial LLC’s holdings in Regeneron Pharmaceuticals were worth $851,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. West Paces Advisors Inc. increased its holdings in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the period. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $26,000. Sachetta LLC raised its position in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $28,000. Finally, Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $33,000. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Wells Fargo & Company reiterated an “overweight” rating and set a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, September 23rd. Finally, Leerink Partners restated a “market perform” rating and set a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,118.62.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $1,042.69 on Friday. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The firm has a 50 day moving average of $1,128.91 and a two-hundred day moving average of $1,035.02. The firm has a market capitalization of $114.95 billion, a PE ratio of 30.80, a P/E/G ratio of 3.57 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the previous year, the firm posted $8.79 earnings per share. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares in the company, valued at $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders sold a total of 9,270 shares of company stock valued at $10,695,833 in the last quarter. 7.48% of the stock is currently owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.